/
Press releaseGothenburg SwedenAugust 182021 CEST Press releaseGothenburg SwedenAugust 182021 CEST

Press releaseGothenburg SwedenAugust 182021 CEST - PDF document

davies
davies . @davies
Follow
346 views
Uploaded On 2021-09-09

Press releaseGothenburg SwedenAugust 182021 CEST - PPT Presentation

Introducing BICO The Global Leader in the Bio Convergence RevolutionCELLINK Life Sciences has transformitself to create a more growthorientedbusiness structure for faster life science innovationsTo be ID: 878185

press bico health 146 bico press 146 health company create life technologies future science faster customers enable convergence bio

Share:

Link:

Embed:

Download Presentation from below link

Download Pdf The PPT/PDF document "Press releaseGothenburg SwedenAugust 182..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

1 Press releaseGothenburg, SwedenAugust 18
Press releaseGothenburg, SwedenAugust 18,2021, (CEST) Introducing BICO: The Global Leader in the Bio Convergence Revolution CELLINK Life Sciences has transformitself to create a more growthorientedbusiness structure for faster life science innovationsTo better reflect the new structure and all the opportunities that lies within, the Group has changed name to BICO ( Press releaseGothenburg, SwedenAugust 18,2021, (CEST) continued to grow, we saw limitations to make radical change in the industry at our customers’ laboratories with just one product. We realized that our customers needed more and better technologies, products, solutions, and workflows for the most optimal outcome where we together can create the most change. I am proud to introduce BICO to the world and look forward to continuing to push the boundaries of science to create the future of health.The company will be focused around five central areas, including the enabling of safer and accessible organ transplants, utilization of cultivated tissue from human cells to eliminate unnecessary animal testing, faster development of more affordable medicines, more personalized medicines, as well as faster and less expensive diagnostics to fight infectious diseases. Today’s healthcare challenges require complex and multifaceted solutions. The bio convergence principle embodies this novel approach and will enable researchers to uncover the answers to shape the future of health”, said Dr. Robert Langer, professor at the Massachusetts Institute of Technology, cofounder of Moderna and member of the BICO cientific dvisory oard. “I’m excited to continue to work with BICO and am eager to see the progres

2 s they make.The subsidiaries that are a
s they make.The subsidiaries that are a part of BICO will keep their names and operate as individual companies.he companyticker has been updated from CLNK to BICO. There have been no additional changes to the company's financial instruments.BICO press kit availablein press roomsectionon www.bico.com . For further information, please contact: Isabelle Ljunggren, Head of Communications Phone (Sweden): +46 7830 0890 Emailil@bico.com BICO Press office Phone(US)Riley Munks, PR Manager (650) 8636699Alyssa D’OrazioPR Manager 617) 6349601 Email: press@bico.com This information was submitted for publication, through the agency of the contact person set out above, on August 182021,at pm (CEST).About BICO Founded in 2016, BICO(formerly CELLINK)is the leading bio convergence company in the worldy combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform highthroughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,85publications. BICO is listed on the Nasdaq the Stockholm under BICO.www.bico.co